Model Number 3CX*FX25RWC |
Device Problem
Use of Device Problem (1670)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 09/14/2023 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.H6: component code: 4739 - gas exchanger health effect - impact code: 2199 - no health consequences or impact health effect - clinical code: 4582 - no clinical signs, symptoms or conditions medical device problem code: 1670 - use of device problem investigation findings: 3233 - results pending completion of investigation investigation conclusions: 11 - conclusion not yet available.
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, as perfusion continued, a decline in performance became apparent, the oxygenation worsened.*no known health consequences or impact to patient *product was not changed out *procedure completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H4 (device manufacture date).H6 (identification of evaluation codes 10, 3331, 213, 67).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 3331 - analysis of production records.Investigation findings: 213 - no device problem found.Investigation conclusions: 67 - no problem detected.The affected sample was visually inspected upon receipt with no anomaly such as breakage.The unit was then rinsed and dried, and the amount of oxygen transfer and carbon dioxide gas removal were measured, according to the product inspection procedure.It was confirmed to have met the factory's specifications, with no anomalies found.Contents of blood gas data was also reviewed.The cause of the occurrence could not be clarified as the returned sample was found to have no anomaly.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
Oxygenation worsened.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 24, 2023.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
Oxygenation worsened.
|
|
Search Alerts/Recalls
|
|